Abstract
The authors are to be commended for working out the pharmacokinetic profile of the polyethylene glycol (PEG) doxorubicin-eluting microsphere (Lifepearl; Terumo Europe, Leuven, Belgium) and demonstrating the safety of this device for the treatment of Child-Pugh A patients with hepatocellular carcinoma, more than half of whom had solitary tumors published in this issue of Journal of Vascular and Interventional Radiology (1). The patients had Barcelona Clinic for Liver Cancer stage A or B disease; patients with a performance status of >0 or metastatic disease were excluded.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
